498 related articles for article (PubMed ID: 26417057)
1. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
Hagström E; James SK; Bertilsson M; Becker RC; Himmelmann A; Husted S; Katus HA; Steg PG; Storey RF; Siegbahn A; Wallentin L;
Eur Heart J; 2016 Apr; 37(16):1325-33. PubMed ID: 26417057
[TBL] [Abstract][Full Text] [Related]
2. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
[TBL] [Abstract][Full Text] [Related]
4. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Lindholm D; Hagström E; James SK; Becker RC; Cannon CP; Himmelmann A; Katus HA; Maurer G; López-Sendón JL; Steg PG; Storey RF; Siegbahn A; Wallentin L
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28411246
[TBL] [Abstract][Full Text] [Related]
5. Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial.
Ueland T; Åkerblom A; Ghukasyan T; Michelsen AE; Aukrust P; Becker RC; Bertilsson M; Himmelmann A; James SK; Siegbahn A; Storey RF; Kontny F; Wallentin L;
J Am Heart Assoc; 2018 Jan; 7(2):. PubMed ID: 29330256
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome.
Lindholm D; James SK; Bertilsson M; Becker RC; Cannon CP; Giannitsis E; Harrington RA; Himmelmann A; Kontny F; Siegbahn A; Steg PG; Storey RF; Velders MA; Weaver WD; Wallentin L;
Clin Chem; 2017 Feb; 63(2):573-584. PubMed ID: 27932413
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Patel MR; Becker RC; Wojdyla DM; Emanuelsson H; Hiatt WR; Horrow J; Husted S; Mahaffey KW; Steg PG; Storey RF; Wallentin L; James SK
Eur J Prev Cardiol; 2015 Jun; 22(6):734-42. PubMed ID: 24830710
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Based Prediction of Recurrent Ischemic Events in Patients With Acute Coronary Syndromes.
Batra G; Lindbäck J; Becker RC; Harrington RA; Held C; James SK; Kempf T; Lopes RD; Mahaffey KW; Steg PG; Storey RF; Swahn E; Wollert KC; Siegbahn A; Wallentin L
J Am Coll Cardiol; 2022 Nov; 80(18):1735-1747. PubMed ID: 36302586
[TBL] [Abstract][Full Text] [Related]
9. Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy.
Sumaya W; Wallentin L; James SK; Siegbahn A; Gabrysch K; Bertilsson M; Himmelmann A; Ajjan RA; Storey RF
Eur Heart J; 2018 Apr; 39(13):1078-1085. PubMed ID: 29390064
[TBL] [Abstract][Full Text] [Related]
10. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease.
Hagström E; Held C; Stewart RA; Aylward PE; Budaj A; Cannon CP; Koenig W; Krug-Gourley S; Mohler ER; Steg PG; Tarka E; Östlund O; White HD; Siegbahn A; Wallentin L;
Clin Chem; 2017 Jan; 63(1):325-333. PubMed ID: 27811204
[TBL] [Abstract][Full Text] [Related]
11. Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study.
Sumaya W; Wallentin L; James SK; Siegbahn A; Gabrysch K; Himmelmann A; Ajjan RA; Storey RF
Thromb Haemost; 2020 Mar; 120(3):412-422. PubMed ID: 31975352
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy.
Giannitsis E; Wallentin L; James SK; Bertilsson M; Siegbahn A; Storey RF; Husted S; Cannon CP; Armstrong PW; Steg PG; Katus HA;
Eur Heart J Acute Cardiovasc Care; 2017 Sep; 6(6):500-510. PubMed ID: 27044282
[TBL] [Abstract][Full Text] [Related]
13. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Held C; Asenblad N; Bassand JP; Becker RC; Cannon CP; Claeys MJ; Harrington RA; Horrow J; Husted S; James SK; Mahaffey KW; Nicolau JC; Scirica BM; Storey RF; Vintila M; Ycas J; Wallentin L
J Am Coll Cardiol; 2011 Feb; 57(6):672-84. PubMed ID: 21194870
[TBL] [Abstract][Full Text] [Related]
14. GDF-15 at admission predicts cardiovascular death, heart failure, and bleeding outcomes in patients with CAD.
Wang J; Zhang T; Xu F; Gao W; Chen M; Zhu H; Xu J; Yin X; Pang J; Zhang S; Wei M; Chen J; Liu Y; Yu X; Chew DP; Chen Y
ESC Heart Fail; 2023 Oct; 10(5):3123-3132. PubMed ID: 37620152
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
James S; Budaj A; Aylward P; Buck KK; Cannon CP; Cornel JH; Harrington RA; Horrow J; Katus H; Keltai M; Lewis BS; Parikh K; Storey RF; Szummer K; Wojdyla D; Wallentin L
Circulation; 2010 Sep; 122(11):1056-67. PubMed ID: 20805430
[TBL] [Abstract][Full Text] [Related]
16. Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Kohli P; Wallentin L; Reyes E; Horrow J; Husted S; Angiolillo DJ; Ardissino D; Maurer G; Morais J; Nicolau JC; Oto A; Storey RF; James SK; Cannon CP
Circulation; 2013 Feb; 127(6):673-80. PubMed ID: 23277305
[TBL] [Abstract][Full Text] [Related]
17. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Ducrocq G; Schulte PJ; Becker RC; Cannon CP; Harrington RA; Held C; Himmelmann A; Lassila R; Storey RF; Sorbets E; Wallentin L; Steg PG
EuroIntervention; 2015 Nov; 11(7):737-45. PubMed ID: 25254357
[TBL] [Abstract][Full Text] [Related]
18. Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: insights from the PLATelet inhibition and patient outcomes (PLATO) trial.
Brilakis ES; Held C; Meier B; Cools F; Claeys MJ; Cornel JH; Aylward P; Lewis BS; Weaver D; Brandrup-Wognsen G; Stevens SR; Himmelmann A; Wallentin L; James SK
Am Heart J; 2013 Sep; 166(3):474-80. PubMed ID: 24016496
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.
Velders MA; Wallentin L; Becker RC; van Boven AJ; Himmelmann A; Husted S; Katus HA; Lindholm D; Morais J; Siegbahn A; Storey RF; Wernroth L; James SK;
Am Heart J; 2015 Jun; 169(6):879-889.e7. PubMed ID: 26027627
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
